Slingshot members are tracking this event:
Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)
Do you think this event is important to the companies below? How will it affect their stock price?
|Impact on Stocks
V920 was initially engineered by scientists from the Public Health Agency of Canada’s National Microbiology Laboratory and subsequently licensed to a subsidiary of NewLink Genetics Corporation. In late 2014, when the peak of the Ebola outbreak in western Africa was at its worst, Merck licensed V920 from NewLink Genetics, with the goal of accelerating the development, licensure, and availability of this candidate vaccine. Since that time, Merck has worked closely with NewLink Genetics and a number of external collaborators to enable a broad clinical development program with funding from the U.S. Government including the Department of Health and Human Service’s Biomedical Advanced Research Development Authority (BARDA) and the Department of Defense’s Defense Threat Reduction Program/Joint Vaccination Acquisition Program (DTRA/JVAP) among others. Additional research evaluating V920 is ongoing.
Slingshot Insights Explained
Jul 25, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Breakthrough Therapy Designation, Prime Status, Ebola Zaire Vaccine, Rvsv∆g-zebov-gp, V920, Priority Medicines